Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire’s board and the proposal is at a “preparatory and exploratory” stage. No information about the investment was revealed by the Japanese drug makers. Takeda after acquiring Shire will flourish in the market of therapeutic areas of oncology, gastrointestinal disorders and neuroscience. The acquisition of Shire’s rare-disease franchise will give an upper hand to Takeda and will pace up its path to become the pioneer in specialised medicine. This will be also profitable to the Shire as this would increase Shire market opportunities in the US. According to the UK acquisition regulations Takeda should give the final decision about its Shire acquisition by April 25. The other pharma companies such as AbbVie, Novartis, Pfizer will still be the part of the bidding process which might lead to higher pricing in the bidding race.
- Global Top Players in Intraocular Lens (IOL) Market
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Which Countries Top the Chart in Global Pharmaceutical Market?
- Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
- How are Nanobots Proving Their Excellence in the Healthcare Industry?
- Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment
Takeda acquisition on Shire raises its share by 25 percent
Mar 28, 2018 | Reading Time: < 1 minutes
AbbVie Presents Phase III CANOVA Study Results; Novartis’ Iptacopan Shows Promise in Phase III Study; Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer; FDA Issues Complete Response Letter for Lebrikizumab; Nedosiran Approveed for Primary Hyperoxaluria Type 1; Orphan Drug Designation to BDC-1001 for Gastric Cancers
AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...Find More
LEQEMBI Intravenous Infusion Approval; Novartis’ Presented Updates on Lutathera; FDA Accepts Submission to Add PH-ILD to YUTREPIA Label; FDA Issues CRL to BLA for Pegfilgrastim-cbqv; FDA Fast Track Designation to Therpay, MWTX-003; EC Approves TEPKINLY (epcoritamab) for R/R DLBCL
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with Polycyt...Find More
Eli Lilly’s Obesity Treatment Drug Candidates – A Show for the Competitors
On 26 June 2023, the rush to develop obesity therapies appeared to have raised the bar, as an experimental weight-loss drug from US pharma company Eli Lilly yielded the greatest effects of any treatment observed thus far. The American Diabetes Association’s annual meeting has brought the competitive dynamics of ...Find More
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.